2.47
2.47 (0%)
As of Feb 14, 2025
Tango Therapeutics, Inc. [TNGX]
Source:
Company Overview
Tango Therapeutics was founded with a clear mission: to discover the next wave of targeted therapies in oncology by addressing the specific genetic alterations that drive cancer. We leverage our state-of-the-art target discovery platform to identify novel targets and develop new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need.
| Country | United States |
| Headquarters | boston, massachusetts |
| Phone Number | (857) 320-4900 |
| Industry | |
| CEO | Tango Therapeutics, Inc. |
| Website | http://www.tangotx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $42.1 |
| Operating Profit | $-145.6 |
| Net Income | $-130.3 |
| Net Cash | $2.3 |
Profit Ratios
| Gross Margin | $42.1 |
| Operating Margin | -346.1 |
| Profit as % of Revenues | -32.3% |
| Profit as % of Assets | -36.2% |
| Profit as % of Stockholder Equity | -65.3% |
Management Effectiveness
| Return on Equity | -65.3% |
| Return on Assets | -41.2% |
| Turnover Ratio | 11.7% |
| EBITA | $-145.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $316.5 |
| Total Liabilities | $117 |
| Operating Cash Flow | $-131.5 |
| Investing Cash Flow | $86.1 |
| Financing Cash Flow | $47.7 |
